From ‘molecules of life’ to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders - Aix-Marseille Université Access content directly
Journal Articles Drug Discovery Today Biosilico Year : 2021

From ‘molecules of life’ to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders

Abstract

The large families of the molecules of life are at the origin of the discovery of new compounds with which to treat disease. The arrival of artificial intelligence (AI) has considerably modified the search for innovative bioactive drugs and their therapeutic applications. Conventional approaches at different organizational research levels have emerged and, thus, AI associated with gene and cell therapies could supplant conventional pharmacotherapy and facilitate the diagnosis of pathologies. Using the examples of chronic pain and neuropathic disorders, which affect a large number of patients, I illustrate here how AI could generate new therapeutic approaches, why some compounds are seen as recreational drugs and others as medicinal drugs, and why, in some countries, psychedelic drugs are considered as potential therapeutic drugs but not in others.
Fichier principal
Vignette du fichier
DDT pub word final 27 01 2021 pdf.pdf (367.4 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03142522 , version 1 (16-02-2021)

Licence

Identifiers

Cite

Jean-Louis Kraus. From ‘molecules of life’ to new therapeutic approaches, an evolution marked by the advent of artificial intelligence: the cases of chronic pain and neuropathic disorders. Drug Discovery Today Biosilico, 2021, ⟨10.1016/j.drudis.2021.01.009⟩. ⟨hal-03142522⟩
57 View
223 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More